167 related articles for article (PubMed ID: 30190702)
1. Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes.
Predieri B; Suprani T; Maltoni G; Graziani V; Bruzzi P; Zucchini S; Iughetti L
Front Endocrinol (Lausanne); 2018; 9():462. PubMed ID: 30190702
[No Abstract] [Full Text] [Related]
2. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
3. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study.
Suzuki J; Yamakawa T; Nagakura J; Shigematsu E; Kadonosono K; Terauchi Y
Diabetol Int; 2017 Mar; 8(1):45-51. PubMed ID: 30603306
[TBL] [Abstract][Full Text] [Related]
5. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
6. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
[TBL] [Abstract][Full Text] [Related]
8. Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).
Miura H; Sakaguchi K; Okada Y; Otowa-Suematsu N; Yamada T; So A; Komada H; Hirota Y; Kishi M; Takeda A; Tominaga Y; Nakamura T; Kuroki Y; Matsuda T; Iida K; Kajikawa M; Ohara T; Yokota K; Hara K; Tateya S; Tamori Y; Ogawa W
Diabetes Ther; 2018 Dec; 9(6):2399-2406. PubMed ID: 30341665
[TBL] [Abstract][Full Text] [Related]
9. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
[TBL] [Abstract][Full Text] [Related]
10. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
[No Abstract] [Full Text] [Related]
13. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial.
Vrebalov Cindro P; Krnić M; Modun D; Vuković J; Tičinović Kurir T; Kardum G; Rušić D; Šešelja Perišin A; Bukić J
JMIR Form Res; 2022 Jul; 6(7):e35655. PubMed ID: 35802405
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes.
Urakami T; Kuwabara R; Aoki M; Okuno M; Suzuki J
Endocr J; 2016; 63(2):159-67. PubMed ID: 26632171
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population.
Kochar IS; Sethi A
Int J Pediatr Endocrinol; 2018; 2018():6. PubMed ID: 30069184
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Onishi Y; Iwamoto Y; Yoo SJ; Clauson P; Tamer SC; Park S
J Diabetes Investig; 2013 Nov; 4(6):605-12. PubMed ID: 24843715
[TBL] [Abstract][Full Text] [Related]
19. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.
Long T; Lin JT; Lin MH; Wu QL; Lai JM; Li SZ; Zhou ZC; Zeng JY; Huang JS; Zeng CP; Lai YM
Endocr J; 2022 Aug; 69(8):959-969. PubMed ID: 35431280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
